Multiple-Dose Pharmacodynamics and Pharmacokinetics of Anacetrapib, a Potent Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Healthy Subjects

被引：90

作者：

Krishna, R. ^{[1
]}

Bergman, A. J. ^{[1
]}

Jin, B. ^{[1
]}

Fallon, M. ^{[1
]}

Cote, J. ^{[1
]}

Van Hoydonck, P. ^{[1
]}

Laethem, T. ^{[1
]}

Gendrano, I. N., III ^{[1
]}

Van Dyck, K. ^{[1
]}

Hilliard, D. ^{[1
]}

Laterza, O. ^{[1
]}

Snyder, K. ^{[1
]}

Chavez-Eng, C. ^{[1
]}

Lutz, R. ^{[1
]}

Chen, J. ^{[1
]}

Bloomfield, D. M. ^{[1
]}

De Smet, M. ^{[1
]}

Van Bortel, L. M. ^{[2
]}

Gutierrez, M. ^{[3
]}

Al-Huniti, N. ^{[4
]}

Dykstra, K. ^{[4
]}

Gottesdiener, K. M. ^{[1
]}

Wagner, J. A. ^{[1
]}

机构：

[1] Merck & Co Inc, Whitehouse Stn, Whitehouse Stn, NJ USA

[2] Ghent Univ Hosp, Drug Res Unit Ghent, B-9000 Ghent, Belgium

[3] Comprehens Phase One Inc, Miramar, FL USA

[4] Pharsight Corp, Cary, NC USA

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2008年 / 84卷 / 06期

关键词：

D O I：

10.1038/clpt.2008.109

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Cholesteryl ester transfer protein (CETP) is a plasma protein that catalyzes the heteroexchange of cholesteryl esters from high-density lipoprotein (HDL) and trglycerides to apolipoprotein B-containing lipoproteins, especially very low-density lipoproteins (LDL-C).(1,2)

引用

页码：679 / 683

页数：5

共 50 条

[1] Single-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects
Krishna, Rajesh
Garg, Amit
Panebianco, Deborah
Cote, Josee
Bergman, Arthur J.
Van Hoydonck, Pascale
Laethem, Tine
Van Dyck, Kristien
Chen, Jingjing
Chavez-Eng, Cynthia
Archer, Laura
Lutz, Ryan
Hilliard, Deborah
Snyder, Karen
Jin, Bo
Van Bortel, Luc
Lasseter, Kenneth C.
Al-Huniti, Nidal
Dykstra, Kevin
Gottesdiener, Keith
Wagner, John A.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 68 (04) : 535 - 545
[2] Pharmacokinetics, Safety and Tolerability of Anacetrapib, a Novel Cholesteryl Ester Transfer Protein (CETP) Inhibitor, After Single and Multiple Doses in Healthy Chinese Subjects
Hanjing Chen
Weili Chen
Hui Li
Hongrong Xu
Fei Yuan
Lei Sheng
Chao Liu
Pingping Lin
Mengjie Yang
Xuening Li
Yang Liu
Brittany Marie Walker
Ferdous Gheyas
Marian Iwamoto
S. Aubrey Stoch
Rajesh Krishna
Advances in Therapy, 2021, 38 : 3973 - 3985
[3] Pharmacokinetics, Safety and Tolerability of Anacetrapib, a Novel Cholesteryl Ester Transfer Protein (CETP) Inhibitor, After Single and Multiple Doses in Healthy Chinese Subjects
Chen, Hanjing
Chen, Weili
Li, Hui
Xu, Hongrong
Yuan, Fei
Sheng, Lei
Liu, Chao
Lin, Pingping
Yang, Mengjie
Li, Xuening
Liu, Yang
Walker, Brittany Marie
Gheyas, Ferdous
Iwamoto, Marian
Stoch, S. Aubrey
Krishna, Rajesh
ADVANCES IN THERAPY, 2021, 38 (07) : 3973 - 3985
[4] Assessment of a pharmacokinetic and pharmacodynamic interaction between simvastatin and anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects
Krishna, Rajesh
Garg, Amit
Jin, Bo
Keshavarz, Sara Sadeghi
Bieberdorf, Frederick A.
Chodakewitz, Jeffrey
Wagner, John A.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 67 (05) : 520 - 526
[5] Tolerability, pharmacokinetics and pharmacodynamics of TA-8995, a selective cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects
Ford, John
Lawson, Matt
Fowler, David
Maruyama, Nobuko
Mito, Seiji
Tomiyasu, Koichi
Kinoshita, Shuji
Suzuki, Chisa
Kawaguchi, Atsuhiro
Round, Patrick
Boyce, Malcolm
Warrington, Steve
Weber, Werner
van Deventer, Sander
Kastelein, John J. P.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 78 (03) : 498 - 508
[6] Effect of Diltiazem, a Moderate CYP3A Inhibitor, on the Pharmacokinetics of Anacetrapib, a Potent Cholesteryl Ester Transfer Protein Inhibitor, in Healthy Subjects
Garg, Amit
Maes, Andrea
Corr, Christy
Jin, Bo
Wadhwa, Tarun
Handa, Nikhil
Van Dyck, Kristien
De Lepeleire, Inge
Shah, Jinesh
Wagner, John A.
Krishna, Rajesh
JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 51 (03): : 436 - 439
[7] Quantitative Prediction of Human Pharmacokinetics and Pharmacodynamics of CKD519, a Potent Inhibitor of Cholesteryl Ester Transfer Protein (CETP)
Choi, Suein
Han, Seunghoon
Jeon, Sangil
Yim, Dong-Seok
PHARMACEUTICS, 2019, 11 (07)
[8] Assessment of the CYP3A4-mediated drug interaction potential of anacetrapib (ANA), a potent Cholesteryl Ester Transfer Protein (CETP) inhibitor, in healthy subjects
Krishna, R.
Bergman, A. J.
Jin, B.
Garg, A.
Roadcap, B.
Clriou, R.
Dru, J.
Cote, J.
Laethem, T.
Vets, E.
Avery, P.
Gottesdiener, K.
Wagner, J. A.
JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 48 (09): : 1105 - 1105
[9] Anacetrapib, a cholesteryl ester transfer protein inhibitor
Hooper, Amanda J.
Burnett, John R.
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2012, 21 (01) : 103 - 109
[10] SINGLE DOSE PHARMACODYNAMICS AND PHARMACOKINETICS OF DRL-17822, A POTENT CETP INHIBITOR, IN HEALTHY SUBJECTS
Hasham, S.
Mangapathiraju, T.
Vittal, S.
Bapat, A.
Rao, M.
Sai, S.
Shanavas, A.
Allenby, K.
Kumar, R.
ATHEROSCLEROSIS SUPPLEMENTS, 2010, 11 (02) : 181 - 181

← 1 2 3 4 5 →